NextFin News - Novartis shares opened lower in Zurich trading on Tuesday after the Swiss drugmaker said its experimental muscular-dystrophy treatment del-desiran failed to meet the primary goal of a late-stage trial, the second high-profile clinical setback in less than a week and a fresh test of the $12 billion bet the company made on RNA therapies last year. The stock gapped down from a prior close of 129.58 francs to open at 124.64 francs, a decline of about 3.8%, and traded in a range of 124.60 to 127.22 francs as investors weighed the news. The global Phase III HARBOR study did not show a statistically significant improvement versus placebo on its primary endpoint of video hand opening time (vHOT), a measure of hand muscle stiffness in myotonic dystrophy type 1 (DM1), the company said in a Sept. 8 ad hoc announcement filed under SIX Swiss Exchange rules. The trial enrolled approximately 150 patients over 54 weeks.
The miss arrives two trading days after Novartis disclosed that pelacarsen, its experimental cholesterol drug, failed to reduce heart attacks and strokes in the large Lp(a)HORIZON cardiovascular outcomes trial - a result that knocked 3.3% off the stock on Monday. Together, the two failures put a spotlight on the pipeline Novartis has been counting on to offset patent expirations for older blockbusters such as the heart drug Entresto, and on the antibody oligonucleotide conjugate (AOC) platform it bought through its acquisition of Avidity Biosciences.
Novartis said del-desiran showed evidence of clinical activity in secondary endpoints and exploratory analyses, that safety findings were generally consistent with previously reported data, and that it is evaluating the full dataset before deciding on the drug's development path with health authorities. The company also reaffirmed its guidance for sales to grow at a compound annual rate of 5% to 6% from 2025 to 2030. But for investors who had been leaning on del-desiran, delpacibart zotadirsen and delpacibart braxlosiran - the three neuromuscular AOC therapies that came with Avidity - the question is no longer whether one trial can miss. It is whether the platform that justified a $12 billion price tag still converts biomarker engagement into clinical benefit.
Two Blows in Less Than a Week: What Failed, and What Still Stands
The sequence matters because the two failures hit different parts of the same growth thesis, and the market is now forced to price both at once. Pelacarsen was the cardiovascular hope: the Lp(a)HORIZON trial enrolled 8,323 patients with elevated lipoprotein(a) and established cardiovascular disease, and while the drug lowered the blood fat, that reduction did not translate into fewer heart attacks, strokes or other serious cardiovascular events. It is the classic failure mode of lipid medicine - move the biomarker, miss the outcome - and it immediately cast doubt on the wider industry effort to target Lp(a), an inherited risk factor that affects roughly one in five people worldwide and has no approved treatments.
The DM1 miss is the neuromuscular hope. Del-desiran is an investigational AOC built to bind the transferrin receptor 1 on muscle cells and ferry a small interfering RNA into those cells, where it is designed to degrade the toxic DMPK messenger RNA that drives the disease. DM1 is a progressive, multisystem disorder caused by an expansion of CTG repeats in the DMPK gene, and there are still no approved treatments. The vHOT endpoint - a machine-learning-based measure of hand opening that quantifies hand myotonia - is novel, and the company aligned with global regulators on the registrational path before HARBOR began. Novartis said it observed clinical activity in secondary endpoints and exploratory analyses, and that it will engage health authorities on the most appropriate development path. That is not the language of a program being shut down; it is the language of a company negotiating what a miss on one endpoint means for a disease with no alternatives.
Yet the two setbacks are not symmetrical in what they take off the table. The other two AOC assets are on separate regulatory tracks that the HARBOR result does not directly touch. Delpacibart zotadirsen has been filed for accelerated FDA approval for Duchenne muscular dystrophy in patients with mutations amenable to exon 44 skipping and has been granted priority review. Delpacibart braxlosiran is the subject of a planned FDA meeting on next steps for facioscapulohumeral muscular dystrophy, based on positive Phase I/II biomarker data. The DM1 failure removes one leg of the Avidity stool; it does not collapse the other two. But it does remove the asset that was supposed to read out in the fourth quarter and, in the view of some analysts, the one most needed to justify the acquisition.
"Despite decades of research, there are still no approved treatment options for DM1, and patients and caregivers continue to face a significant daily burden," said Shreeram Aradhye, Novartis's president of development and chief medical officer. "Developing therapies for a complex disease like DM1 remains challenging, and setbacks are part of scientific progress."
Why the Avidity Bet Now Carries the Weight of a Patent Cliff
The market's reaction is not just about one rare-disease trial. It is about timing, and about what Novartis needs the Avidity deal to do. The acquisition was announced in October 2025 at approximately $12 billion - about $72 a share, a 46% premium to Avidity's closing price - and closed in 2026, giving Novartis a late-stage neuromuscular RNA pipeline just as its own older blockbusters approach patent expiry. Entresto, the heart failure franchise that generated $1.3 billion in first-quarter 2026 sales but declined 42% at constant currency year over year, is the clearest example of the revenue hole new launches must fill if the 5% to 6% sales CAGR guidance for 2025-2030 is to hold.
That guidance is still intact, and it is the anchor management offered on Tuesday. But guidance is a multi-year, portfolio-level promise, and the market prices the marginal asset. Before the pelacarsen result, analysts had forecast peak annual sales for that drug alone in the range of $3 billion to $6 billion if it succeeded. With that hope gone, more of the growth narrative shifts onto the AOC trio - and now, effectively, onto the two assets that have not yet read out in Phase III. Barclays analysts said success in the del-desiran trial "is needed to justify" the high price tag of the Avidity acquisition. After Tuesday, that justification rests more heavily on delpacibart zotadirsen's accelerated-approval decision and on delpacibart braxlosiran's biomarker-to-function translation.
The pressure is compounded by the concentration of binary events. The cholesterol miss and the DM1 miss arrive before the Duchenne decision, before the FSHD meeting outcome, and before any readout on other late-stage candidates such as the remibrutinib program in multiple sclerosis. A string of pipeline catalysts clustered in a single quarter is exactly the kind of concentration that makes a diversified pharma stock with a beta of 0.49 behave like a biotech name - and pharma investors, who own these shares for stability and dividends, do not always price that kind of risk generously when it materializes.
The Second-Order Question: Platform Problem or Molecule Problem?
The first-order effect of the HARBOR miss is straightforward: one less near-term revenue stream, and a stock that has given back part of its advance. The second-order question - the one the market is really asking - is what the failure says about the AOC mechanism itself, and by extension about the wider field of RNA delivery to muscle.
There is a plausible read under which the two failures are unrelated. Pelacarsen is an antisense oligonucleotide that lowers a lipid biomarker; its failure is a clinical-outcome failure, the classic "the biomarker moved but patients did not benefit" problem that has haunted lipid medicine for years. Del-desiran's miss is on a functional endpoint in a rare neuromuscular disease where the endpoint itself - video hand opening time - is new and unproven as a regulatory surrogate. Under that reading, the AOC delivery platform is not on trial; one molecule in one disease with a novel endpoint is.
But the market will also run the propagation chain one step further, and this is where the risk compounds. If the AOC platform cannot convert biomarker engagement into functional benefit in DM1 - a disease where the genetic target is clean and the mechanism is direct - investors will ask whether the same delivery system can do it in Duchenne and FSHD. The concern is not that delpacibart zotadirsen or delpacibart braxlosiran share del-desiran's target; they do not. The concern is that they share its delivery technology. An antibody-oligonucleotide conjugate is only as good as its ability to move a clinical endpoint, and HARBOR did not move its primary one.
The counterweight is the regulatory design. Delpacibart zotadirsen is not seeking approval on a functional endpoint in a 150-patient trial. It is pursuing accelerated approval, which can rest on a biomarker or surrogate reasonably likely to predict clinical benefit - dystrophin production in exon 44-skipping DMD - with confirmatory trials to follow. That is a lower evidentiary bar for the initial decision, and it means the Duchenne asset can win commercially even if the DM1 functional story is muddied. The FSHD program, meanwhile, is still at the biomarker-and-meeting stage. The platform's fate is being adjudicated on three different evidentiary tracks, not one - and that dispersion is the strongest argument that HARBOR is an isolated disappointment rather than a platform indictment.
The Counter-Case: When Two Failures Are a Pattern, Not Noise
The strongest argument against a quick "buy the dip" reading is simple, and it deserves weight: two late-stage failures in less than a week is a pattern that cannot be dismissed as a single bad draw. Both assets came from the same acquisition, both sit in the RNA and oligonucleotide family, and both were central to the growth story investors were told to underwrite. A skeptic would say the common denominator is not bad luck - it is a company that paid $12 billion for a platform whose clinical translation is now in question twice over.
That view has institutional backing. After the pelacarsen result, analysts at William Blair noted the risk to the broader Lp(a) field, observing that it may be that pelacarsen did not reduce Lp(a) enough to see an effect - the drug has lowered levels by as much as 72% in past studies, while RNA interference candidates from Amgen and Eli Lilly reduce Lp(a) by more than 90%. Citi analysts expressed a similar view, writing that while deeper Lp(a) inhibition might still be worth pursuing in higher-risk subgroups, they saw "meaningful risk to a potential future in Lp(a)-driven CVD trials." The same logic can be turned on the neuromuscular side: if an AOC can engage its target but not move function, the field - including competitors working on RNA delivery to muscle - faces a repricing of what the technology can deliver.
The falsifying signal for the "platform intact" thesis is specific and observable. If the FDA declines delpacibart zotadirsen's accelerated approval for DMD44, or if delpacibart braxlosiran's upcoming data fail to show functional benefit beyond biomarkers, the case that HARBOR was an isolated endpoint miss collapses. A second no-decision or failure on the remaining AOC assets would convert two setbacks into a platform problem, and the $12 billion acquisition would move from "early pipeline risk" to "capital misallocation."
Conversely, the signal that would vindicate the platform view is equally concrete: an FDA approval of delpacibart zotadirsen on the accelerated pathway, or a positive confirmatory biomarker-to-function readout from del-brax. Either would demonstrate that the AOC mechanism can produce what regulators accept as clinical benefit, isolating HARBOR as a disease-and-endpoint-specific disappointment rather than a technology indictment.
What to Watch Next
Three things will determine whether this is a cyclical drawdown in a still-intact story or the start of a structural de-rating. First, what Novartis does with del-desiran: a decision to pursue an alternative endpoint, a subgroup analysis, or a different dosing regimen would signal management still sees a path; a full discontinuation would not. Second, the FDA's decision timeline on delpacibart zotadirsen's priority review - the single largest remaining catalyst for the Avidity thesis. Third, the outcome of the planned FDA meeting on delpacibart braxlosiran in FSHD, which will reveal whether regulators see the biomarker data as sufficient to advance.
For the stock, the time horizons point in different directions. In the short term, sentiment is negative and likely to stay that way until the next binary readout; a string of misses has a way of making investors discount the next asset before it reports. Over the medium term, the fundamentals hinge on whether the Duchenne and FSHD programs convert - and on whether the 5% to 6% CAGR guidance can be met without the cholesterol drug and with one neuromuscular asset impaired. Over the long term, the question is structural: does targeted RNA delivery to muscle become a repeatable way to build medicines, or does it join the long list of elegant mechanisms that work in the lab and disappoint in people?
Base case: Novartis finds a narrower development path for del-desiran, delpacibart zotadirsen wins accelerated approval in DMD44, and the stock stabilizes as the Avidity thesis narrows from three legs to two. Upside case: del-brax data surprise to the upside and the FDA embraces the AOC platform, turning this quarter's setbacks into a footnote. Downside case: the FDA pushes back on accelerated approval and Novartis drops del-desiran, forcing a reassessment of what the $12 billion bought.
The real story of these days is not that Novartis lost two drugs. It is that the market is being asked to decide whether a $12 billion platform is worth three chances or none - and the answer will come not from management's reassurances, but from the next FDA decision letter.
Explore more exclusive insights at nextfin.ai.
